Steve Pakola, serving as the Chief Medical Officer for REGENXBIO Inc. (NASDAQ:RGNX), has executed a series of stock transactions resulting in the disposal of common shares valued at $688,755. These activities were formally documented in a Form 4 filing submitted to the Securities and Exchange Commission. The transactions were carried out at share prices ranging between $11.04 and $12.86. This insider selling activity occurs against a backdrop of recent price appreciation for REGENXBIO shares, which have climbed 27.83% over the preceding week. The stock is currently trading at $13.10, a level that aligns closely with the InvestingPro Fair Value estimate of $12.75, suggesting the current market price reflects fair valuation. Market indicators from InvestingPro Tips highlight that the stock is exhibiting overbought conditions, although the company's balance sheet shows liquid assets that remain sufficient to cover short-term obligations.
The specific transactions were executed on two distinct dates. On June 29, 2026, Mr. Pakola disposed of 19,608 shares of REGENXBIO common stock. These shares were sold at a weighted average price of $11.04, with individual trades executed at prices ranging from $11.00 to $11.18. Subsequently, on July 1, 2026, Mr. Pakola exercised options to acquire 36,725 shares of common stock at a price of $7.86 per share, totaling $288,658. These options were part of a previously granted award, with 25% vesting on January 2, 2026, and the remainder vesting in equal monthly installments over the subsequent 36 months. Immediately following this acquisition, Mr. Pakola sold all 36,725 shares at a price of $12.86 per share.
All of the reported transactions were executed pursuant to a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for buying or selling company stock to avoid accusations of insider trading. Following these transactions, Mr. Pakola directly owns 213,009 shares of REGENXBIO common stock. He also holds 66,973 derivative shares in the form of stock options.
In other recent news, Regenxbio Inc. announced the dosing of the first patient in its Phase IIb/III NAAVIGATE clinical trial for diabetic retinopathy, a significant milestone that will bring in $100 million from AbbVie. H.C. Wainwright reiterated a Buy rating and a $26.00 price target for Regenxbio following this development. Additionally, the company has completed dosing in the confirmatory study of RGX-202, a gene therapy candidate for Duchenne muscular dystrophy, ahead of schedule. Regenxbio plans to submit a Biologics License Application for RGX-202 under the accelerated approval pathway in the third quarter of 2026, with potential FDA approval anticipated in the second half of 2027. H.C. Wainwright also reaffirmed its Buy rating and price target after the completion of this study.
In another development, Regenxbio has aligned with the FDA on resubmitting the Biologics License Application for NAVSUNLI, a treatment for Mucopolysaccharidosis II. The FDA has acknowledged that the existing clinical data are sufficient for consideration under the accelerated approval pathway. H.C. Wainwright reiterated its Buy rating and $26.00 price target after this announcement as well. These recent developments highlight Regenxbio’s ongoing progress in its clinical trials and regulatory pathways.